Clinical Trials 

Clinical trials help researchers answer important medical questions, providing information that may help with the development of future treatment options. Clinical trials are conducted to determine if investigational treatments (such as new drugs, procedures, or medical devices) are safe and effective, so that the regulatory authority can decide whether they can be approved for use as a treatment. 

Participation in a clinical trials is voluntary. You can withdraw at any time and for any reason (or no reason at all) – and doing so will not affect the care you may be receiving now and may receive in the future.

For the most current list of clinical trials (as seen on the national platform for clinical trials;, please click on the following links:

Progressive Supranuclear Palsy
Corticobasal Degeneration
Multiple System Atrophy

In order to receive updates on clinical trials, please register with the FTD Disorder Registry or contact us at +1 347-294-2871 or at


CurePSP is currently in partnership on the following clinical trials:


AbbVie Pharmaceuticals

The purpose of this study is to assess efficacy, safety, tolerability, and pharmacokinetics of ABBV-8E12 in subjects with progressive supranuclear palsy (PSP).

For more information contact the AbbVie Call Center at +1 847-283-8955 or click here.



Biogen is now recruiting for PASSPORT, a placebo-controlled clinical trial to evaluate the effectiveness and safety of an intravenously administered investigational study drug in participants with PSP.

For more information contact the Biogen Call Center at +1 866-633-4636 or click here.

Clinical Research Studies



The Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) consortium is dedicated to conducting clinical research in PSP, CBD, and related diseases. There are currently 14 clinical study sites in the United States and Canada. To learn more about this study, please click here.



The 4 Repeat Tauopathy Neuroimaging Initiative. The goal of this study is to identify the most reliable methods of analysis for tracking CBD and PSP over time. The results from this study may be used in the future to calculate statistical power for clinical drug trials. The study will also provide information about the relative value of novel imaging techniques for diagnosis, as well as the value of imaging techniques versus testing of blood, urine and cerebrospinal fluid (CSF) ‟biomarkers.” To learn more about this study, please click here.



The FTD Disorders Registry

The Registry is an online database to collect information from those affected by all types of prime of life brain diseases, such as PSP, CBD, and related. Persons diagnosed, (current/former) caregivers, family, and friends can join. As a member of the Registry, you can help us advance the science and move faster toward finding treatments and cures. Join the registry here.